Julian Harrison
Stock Analyst at BTIG
(1.24)
# 3,517
Out of 4,829 analysts
37
Total ratings
32.26%
Success rate
-14.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Initiates: Buy | $40 | $4.11 | +874.42% | 1 | Dec 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $42 | $10.45 | +301.91% | 1 | Dec 19, 2024 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $13.92 | - | 3 | Dec 12, 2024 | |
| ANAB AnaptysBio | Downgrades: Neutral | n/a | $20.01 | - | 2 | Dec 2, 2024 | |
| OTLK Outlook Therapeutics | Maintains: Buy | $50 → $9 | $1.58 | +469.62% | 5 | Nov 29, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Buy | $8 | $1.27 | +532.41% | 4 | Nov 19, 2024 | |
| VYNE VYNE Therapeutics | Initiates: Buy | $8 | $1.23 | +550.41% | 1 | Nov 18, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $56 → $61 | $13.11 | +365.47% | 3 | Sep 26, 2024 | |
| RZLT Rezolute | Maintains: Buy | $13 → $15 | $3.75 | +300.00% | 2 | Sep 10, 2024 | |
| LQDA Liquidia | Maintains: Buy | $29 → $25 | $16.15 | +54.80% | 3 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $51 | $45.51 | +12.06% | 2 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $6.50 | +561.54% | 1 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $15.34 | +160.76% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $8.90 | +135.96% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $40.28 | +6.75% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $4 | $2.37 | +68.78% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.65 | +23,026.73% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $40.40 | -10.89% | 1 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $311.70 | - | 2 | Feb 11, 2022 |
Avalo Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $40
Current: $4.11
Upside: +874.42%
Cartesian Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $42
Current: $10.45
Upside: +301.91%
Keros Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $13.92
Upside: -
AnaptysBio
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $20.01
Upside: -
Outlook Therapeutics
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $1.58
Upside: +469.62%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $1.27
Upside: +532.41%
VYNE Therapeutics
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $1.23
Upside: +550.41%
Viridian Therapeutics
Sep 26, 2024
Maintains: Buy
Price Target: $56 → $61
Current: $13.11
Upside: +365.47%
Rezolute
Sep 10, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $3.75
Upside: +300.00%
Liquidia
Aug 20, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $16.15
Upside: +54.80%
Jul 24, 2024
Maintains: Buy
Price Target: $41 → $51
Current: $45.51
Upside: +12.06%
May 20, 2024
Initiates: Buy
Price Target: $43
Current: $6.50
Upside: +561.54%
May 10, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $15.34
Upside: +160.76%
Apr 12, 2024
Initiates: Buy
Price Target: $21
Current: $8.90
Upside: +135.96%
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $40.28
Upside: +6.75%
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $2.37
Upside: +68.78%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.65
Upside: +23,026.73%
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $40.40
Upside: -10.89%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $311.70
Upside: -